Atea Pharmaceuticals (AVIR) Revenue (2021)

Atea Pharmaceuticals' (AVIR) quarterly Revenue came in at $192.2 million in Q4 2021, up 485.72% quarter-over-quarter from $32.8 million in Q3 2021.

Atea Pharmaceuticals (AVIR) Revenue (2021) Analysis & Trends

Atea Pharmaceuticals' Revenue history runs 1 years deep, the most recent figure standing at $192.2 million for Q4 2021.

On a quarterly basis, Revenue changed N/A year-over-year to $192.2 million in Q4 2021; TTM through Dec 2021 was $351.4 million, a N/A change from a year earlier, with the FY2021 full-year figure at $351.4 million, up 622.49% from the prior year.
Revenue grew to $192.2 million in Q4 2021 per AVIR's latest filing, from $32.8 million in the prior quarter.
Across five years, Revenue topped out at $192.2 million in Q4 2021 and bottomed at $32.8 million in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	1.51 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	2.99 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	3.61 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	1.30 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Atea Pharmaceuticals	374.61 Mn	374.61 Mn	-	-

Download Data